- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
NPS Pharmaceuticals Inc
+ Add to WatchlistNPSP:US
14.9100 USD 0.3400 2.23%
Share
As of 20:10:00 ET on 05/24/2013.
More on NPSP
News for NPS Pharmaceuticals Inc (NPSP)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Orphan Drug Prices Under Siege in Austerity-Minded Europe
- U.S. Stock Options With Biggest Changes in Implied Volatility
- NPS Buys Back Rights to Gattex From Takeda to Spur Sales
- U.S. Stock Options With Biggest Changes in Implied Volatility
- NPS's Nader on Drug Research, Growth Strategy
- Largest Nasdaq Short Interest Changes as of Dec. 31
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- NPS Gattex Wins Approval for Short-Bowel Syndrome
- Drug Stocks Prey for Insiders as Industry Resists Change
- NPS Jumps as FDA Staff Backs Risk Plan for Bowel Drug
- NPS Bowel Drug Gattex’s Risk Plan Gains FDA Staff Support
- U.S. Stock Options With Biggest Changes in Implied Volatility
- NPS Pharmaceuticals to Present at Deutsche Bank Health Care Conference Published May 22, 2013
- NPS Pharmaceuticals Prices Public Offering of Common Stock Published May 21, 2013
- NPS Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of its Common Stock Published May 20, 2013
- NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized as Regional Finalist for Ernst & Young Entrepreneur of the Published May 16, 2013
- NPS Pharmaceuticals Recognized by National Organization for Rare Disorders for Gattex® as an Innovative Treatment for Patients Published May 15, 2013
- National Organization for Rare Disorders to Celebrate 30 Years of Achievement and Promote a Promising Future for the Rare Published May 10, 2013
- NPS Pharmaceuticals Reports First Quarter 2013 Financial Results Published May 09, 2013
- NPS Pharmaceuticals to Report First Quarter 2013 Financial Results Published May 01, 2013
- BioNJ To Host 2ND Annual Life Sciences Industry HR Conference on May 20 Published Apr 30, 2013
- NPS Pharmaceuticals Among 100 Best Places to Work in New Jersey for Second Consecutive Year Published Apr 26, 2013
- Siga Liable Over PharmAthene Contract; Damages Set Aside
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Move
- MS Patients Choose Death Risk With Potent Drug Treatment
- Elan Board Unanimously Rejects $6.4 Billion Takeover Offer
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says
- Addex Rises on Positive Rodent Experiment Results: Zurich Mover
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
- Largest Weekly Option Sentiment Changes for S&P 500 Companies
- SAC Digs In as Deadline Nears for U.S. Insider Cases
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Puma Biotech Gains After Rival Drug Data Show No Threat
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page